One kilogram of lactoferrin, a protein most people have never heard of, sells wholesale for up to $1,200. A conventional dairy plant has to process more than 10,000 litres of raw milk to extract it. This week, a British industrial biotech company made a bet that the future of this protein is not in milk at all. It is in a steel tank full of engineered yeast.
On October 15, UK-based Mycofeast acquired Daisy Lab, an Auckland startup that uses precision fermentation to make dairy-identical proteins, with bovine lactoferrin as its most advanced program. Financial terms were not disclosed. The deal keeps Daisy Lab's founding team in place and plugs its fermentation pipeline into a company with industrial-scale bioreactor capacity and commercial operations across Europe and North America.
Milk's $1,000-a-kilo secret
Lactoferrin is an iron-binding protein naturally present in milk, and it is one of the dairy industry's most profitable ingredient fractions. It ends up in infant formula, clinical nutrition products, and functional wellness supplements, markets where buyers pay a premium for purity and batch-to-batch consistency. Wholesale bovine lactoferrin trades at $700 to more than $1,200 per kilogram, a price that reflects how scarce it is in the milk supply: conventional plants recover roughly one kilogram from upwards of 10,000 litres of raw fluid milk, pushed through chromatographic resin columns.
Milk is roughly 87 percent water, and every litre of it is simultaneously the raw material for cheese, butter, powders, and dozens of other products. Extracting a rare fraction means competing for the same raw milk against all of them. That is why traditional dairy processors keep expanding anyway: Germany's DMK Group has invested tens of millions of euros in new milk-extraction capacity, a bet that demand for premium dairy fractions keeps growing. Fermentation companies are making the opposite bet, that brewing the protein in yeast will eventually undercut extraction from milk, the same logic that drove cultivated meat from a $330,000 burger to production breakthroughs.
The deal
Enjoying this story?
Get the five most important stories in tech, every morning. Free.
Daisy Lab was founded in 2021 by Dr. Nikki Freed, Irina Miller, and Emily McIsaac. Over five years the team built a yeast-based platform for recombinant whey proteins, moved its process from bench to an in-house 500-litre pilot fermenter, and reported yields of multiple grams of bovine lactoferrin per litre in May 2025. For context, cow's milk carries roughly 0.02 to 0.2 grams per litre, so the fermentation route delivers a concentration advantage of an order of magnitude or more before downstream processing even begins. New Zealand's Environmental Protection Authority cleared the company in 2024 to scale its platform to 5,000 litres of contained fermentation.
What Mycofeast brings is everything a standalone startup struggles to build: industrial bioreactor capacity, downstream processing infrastructure, and Evolutia Bio, its California R&D subsidiary, which combines AI-driven target discovery, high-throughput automated screening, and genetic engineering to push expression titers higher. The two businesses were already working together as potential partner and customer before acquisition talks began, and Daisy Lab's founders take on roles across the wider group.
Mycofeast wanted both the technology and people. In food tech's consolidation era, teams that have carried a product from bench to pilot are worth as much as the strains they engineered.
The people part matters. Mycofeast confirmed there are no layoffs associated with the acquisition, and co-founder and CEO Irina Miller told Green Queen the group wanted "both the technology and people." Building a precision fermentation team that has carried a product from lab to pilot scale is a five-year job. Buying one takes a quarter. Miller put the logic plainly: over five years the startup had proved the science, improved the process, demonstrated scale-up, and understood where the commercial opportunity sits. What became, in her words, "much less rational" was trying to build every manufacturing and commercial capability around the technology itself.
The consolidation wave
The Lactoferrin Math
Why a milk protein most people have never heard of is worth acquiring a company over.
Note: Figures are reported values from industry sources; bar lengths are illustrative.
This deal is not an outlier. Since late 2024, more than 90 venture-backed food technology and cell-cultivated startups have merged, been acquired, entered restructuring, or ceased operations, as prolonged fundraising cycles collided with the brutal capital math of biomanufacturing. Taking a process from benchtop to thousand-litre pilot scale demands sanitary continuous centrifuges, tangential-flow filtration units, and sterile spray dryers: millions in capital expenditure before a single regulatory dossier is filed. Then comes the multi-year market authorization pathway at the FDA and Europe's EFSA, including the shared documentation needed for Generally Recognized as Safe status.
The industry's answer is increasingly the same: consolidate upstream pipelines into established industrial groups, pool pilot assets, and share regulatory filings. The money is following the same logic elsewhere. Liberation Labs recently secured a $25 million government-backed loan for its first precision fermentation facility, and Abu Dhabi's investment office is exploring a four-million-litre precision fermentation plant with Vivici and The Every Company. Capital is concentrating around whoever owns the tanks and the strains. It is the mirror image of the precision fermentation egg replacer race, where AI is now picking the microbes to speed up development. Here the AI sits inside Evolutia Bio, screening yeast strains for higher titers. Either way the pattern is identical: fermentation's unit economics are becoming a data problem, and the companies with the most data and the biggest tanks win.
What has to happen next
Two milestones decide whether this acquisition looks visionary in hindsight. The first is cost. Fermentation-derived lactoferrin must reach price parity with milk-extracted protein while regulators clear it for sale, a convergence the industry expects to approach heading into 2027. The second is regulatory clearance itself: novel food authorizations across major markets, and the exacting standards of infant formula, the protein's most lucrative destination and one of the most tightly regulated food categories on earth.
The prize is a parallel supply chain for a $1,000-a-kilo ingredient that no longer depends on cows, weather, or dairy markets. Conventional processors are not standing still, and DMK's expansion bet shows the old supply chain has believers. But if Daisy Lab's yeast strains scale inside Mycofeast's tanks the way the pilot numbers suggest, the next thing shrinking the cost of infant formula will not be a bigger dairy plant. It will be a bigger fermenter.
0 Comments